Review



human prostate cancer cell line pc 3  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC human prostate cancer cell line pc 3
    Human Prostate Cancer Cell Line Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 14346 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pm42119785-208-1-19?v=ATCC
    Average 99 stars, based on 14346 article reviews
    human prostate cancer cell line pc 3 - by Bioz Stars, 2026-06
    99/100 stars

    Images



    Similar Products

    99
    ATCC human prostate cancer cell line pc 3
    Human Prostate Cancer Cell Line Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pm42119785-208-1-19?v=ATCC
    Average 99 stars, based on 1 article reviews
    human prostate cancer cell line pc 3 - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC human prostate epithelial cancer cell line
    ( a ) A schematic workflow illustrating the preclinical therapeutic procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 recombinants, severe combined immunodeficient (M-NSG) mice were subject to either single agent or combinatorial treatment in a metronomic schedule of several cycles. The illustration was created in BioRender. ( b ) Comparative statistics of tumor end volumes. PC3 cancer cells were inoculated either alone or combined with PSC27 stromal cells before being implanted subcutaneously to the hind flank of M-NSG animals, which were administered with MIT and SAA, either alone or in combination. ( c ) Representative images of in vivo senescence in tumor foci by SA-β-gal staining. Scale bar, 50 μm. ( d ) Comparative statistics of tumor senescence as described in ( c ). ( e ) Transcriptional analysis of a subset of SASP factors expressed in <t>epithelial</t> vs. stromal cells acquired from tumor foci after laser capture microdissection (LCM) to isolate stromal and cancer cells, respectively. Signals were normalized to that of the sample with lowest value in the placebo group. ( f ) Transcriptional analysis of SASP factors and two canonical senescence biomarkers p16 INK4a and p21 CIP1 . ( g ) Statistical assessment of DDR and cellular apoptosis in tumors. Values are shown as the percentage of cells positively stained by IF or IHC specific to γH2AX or cleaved caspase 3 (CCL3), respectively. ( h ) Representative images of IHC staining for CCL3 at the completion of treatment regimens. Scale bar, 50 μm. ( i ) Comparative survival of animals sacrificed upon development of advanced bulky disease. Survival duration was calculated from tissue recombinant injection until death. P values were calculated by a two-sided log-rank (Mantel-Cox) test. DDR, DNA damage response. IF, immunofluorescence. IHC, immunohistochemistry. Data in b , d , e , f and g are shown as mean ± SD and representative of 3 independent biological replicates, with P values calculated by Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Human Prostate Epithelial Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/bio_rxiv__64898__2026__04__29__721790-321-1-10?v=ATCC
    Average 99 stars, based on 1 article reviews
    human prostate epithelial cancer cell line - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC human prostate cancer cell lines pc 3
    ( a ) A schematic workflow illustrating the preclinical therapeutic procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 recombinants, severe combined immunodeficient (M-NSG) mice were subject to either single agent or combinatorial treatment in a metronomic schedule of several cycles. The illustration was created in BioRender. ( b ) Comparative statistics of tumor end volumes. PC3 cancer cells were inoculated either alone or combined with PSC27 stromal cells before being implanted subcutaneously to the hind flank of M-NSG animals, which were administered with MIT and SAA, either alone or in combination. ( c ) Representative images of in vivo senescence in tumor foci by SA-β-gal staining. Scale bar, 50 μm. ( d ) Comparative statistics of tumor senescence as described in ( c ). ( e ) Transcriptional analysis of a subset of SASP factors expressed in <t>epithelial</t> vs. stromal cells acquired from tumor foci after laser capture microdissection (LCM) to isolate stromal and cancer cells, respectively. Signals were normalized to that of the sample with lowest value in the placebo group. ( f ) Transcriptional analysis of SASP factors and two canonical senescence biomarkers p16 INK4a and p21 CIP1 . ( g ) Statistical assessment of DDR and cellular apoptosis in tumors. Values are shown as the percentage of cells positively stained by IF or IHC specific to γH2AX or cleaved caspase 3 (CCL3), respectively. ( h ) Representative images of IHC staining for CCL3 at the completion of treatment regimens. Scale bar, 50 μm. ( i ) Comparative survival of animals sacrificed upon development of advanced bulky disease. Survival duration was calculated from tissue recombinant injection until death. P values were calculated by a two-sided log-rank (Mantel-Cox) test. DDR, DNA damage response. IF, immunofluorescence. IHC, immunohistochemistry. Data in b , d , e , f and g are shown as mean ± SD and representative of 3 independent biological replicates, with P values calculated by Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Human Prostate Cancer Cell Lines Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pm42042073-83-0-12?v=ATCC
    Average 99 stars, based on 1 article reviews
    human prostate cancer cell lines pc 3 - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC culture conditions human prostate cancer cell lines pc 3
    ( a ) A schematic workflow illustrating the preclinical therapeutic procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 recombinants, severe combined immunodeficient (M-NSG) mice were subject to either single agent or combinatorial treatment in a metronomic schedule of several cycles. The illustration was created in BioRender. ( b ) Comparative statistics of tumor end volumes. PC3 cancer cells were inoculated either alone or combined with PSC27 stromal cells before being implanted subcutaneously to the hind flank of M-NSG animals, which were administered with MIT and SAA, either alone or in combination. ( c ) Representative images of in vivo senescence in tumor foci by SA-β-gal staining. Scale bar, 50 μm. ( d ) Comparative statistics of tumor senescence as described in ( c ). ( e ) Transcriptional analysis of a subset of SASP factors expressed in <t>epithelial</t> vs. stromal cells acquired from tumor foci after laser capture microdissection (LCM) to isolate stromal and cancer cells, respectively. Signals were normalized to that of the sample with lowest value in the placebo group. ( f ) Transcriptional analysis of SASP factors and two canonical senescence biomarkers p16 INK4a and p21 CIP1 . ( g ) Statistical assessment of DDR and cellular apoptosis in tumors. Values are shown as the percentage of cells positively stained by IF or IHC specific to γH2AX or cleaved caspase 3 (CCL3), respectively. ( h ) Representative images of IHC staining for CCL3 at the completion of treatment regimens. Scale bar, 50 μm. ( i ) Comparative survival of animals sacrificed upon development of advanced bulky disease. Survival duration was calculated from tissue recombinant injection until death. P values were calculated by a two-sided log-rank (Mantel-Cox) test. DDR, DNA damage response. IF, immunofluorescence. IHC, immunohistochemistry. Data in b , d , e , f and g are shown as mean ± SD and representative of 3 independent biological replicates, with P values calculated by Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Culture Conditions Human Prostate Cancer Cell Lines Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pm41986660-58-4-26?v=ATCC
    Average 99 stars, based on 1 article reviews
    culture conditions human prostate cancer cell lines pc 3 - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC human prostate cancer cell line pc
    PhIP exposure induces cytotoxicity in RWPE-1 cells and downregulates SLC14A1 expression <t>in</t> <t>PC-3</t> cells. (A) Immunohistochemical staining of SLC14A1 in prostate cancer tissues and normal prostate tissues based on data from the HPA database. (B) Cell viability of RWPE-1 cells after treatment with increasing concentrations of PhIP for 48 h, as determined by CCK-8 assay. (C) Protein expression levels of SLC14A1 in PC-3 cells following PhIP treatment, as assessed by Western blot. (D) Relative mRNA expression levels of SLC14A1 in PC-3 cells after PhIP treatment, as determined by qRT-PCR (**p < 0.01, ***p < 0.001).
    Human Prostate Cancer Cell Line Pc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pmc13106171-118-9-19?v=ATCC
    Average 99 stars, based on 1 article reviews
    human prostate cancer cell line pc - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC human prostate cancer cell line pc3
    PhIP exposure induces cytotoxicity in RWPE-1 cells and downregulates SLC14A1 expression <t>in</t> <t>PC-3</t> cells. (A) Immunohistochemical staining of SLC14A1 in prostate cancer tissues and normal prostate tissues based on data from the HPA database. (B) Cell viability of RWPE-1 cells after treatment with increasing concentrations of PhIP for 48 h, as determined by CCK-8 assay. (C) Protein expression levels of SLC14A1 in PC-3 cells following PhIP treatment, as assessed by Western blot. (D) Relative mRNA expression levels of SLC14A1 in PC-3 cells after PhIP treatment, as determined by qRT-PCR (**p < 0.01, ***p < 0.001).
    Human Prostate Cancer Cell Line Pc3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pm41957092-188-0-12?v=ATCC
    Average 99 stars, based on 1 article reviews
    human prostate cancer cell line pc3 - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC human prostate cancer cell lines pc
    PhIP exposure induces cytotoxicity in RWPE-1 cells and downregulates SLC14A1 expression <t>in</t> <t>PC-3</t> cells. (A) Immunohistochemical staining of SLC14A1 in prostate cancer tissues and normal prostate tissues based on data from the HPA database. (B) Cell viability of RWPE-1 cells after treatment with increasing concentrations of PhIP for 48 h, as determined by CCK-8 assay. (C) Protein expression levels of SLC14A1 in PC-3 cells following PhIP treatment, as assessed by Western blot. (D) Relative mRNA expression levels of SLC14A1 in PC-3 cells after PhIP treatment, as determined by qRT-PCR (**p < 0.01, ***p < 0.001).
    Human Prostate Cancer Cell Lines Pc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pm41937039-133-0-10?v=ATCC
    Average 99 stars, based on 1 article reviews
    human prostate cancer cell lines pc - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC human prostate cancer cell lines pc3
    PhIP exposure induces cytotoxicity in RWPE-1 cells and downregulates SLC14A1 expression <t>in</t> <t>PC-3</t> cells. (A) Immunohistochemical staining of SLC14A1 in prostate cancer tissues and normal prostate tissues based on data from the HPA database. (B) Cell viability of RWPE-1 cells after treatment with increasing concentrations of PhIP for 48 h, as determined by CCK-8 assay. (C) Protein expression levels of SLC14A1 in PC-3 cells following PhIP treatment, as assessed by Western blot. (D) Relative mRNA expression levels of SLC14A1 in PC-3 cells after PhIP treatment, as determined by qRT-PCR (**p < 0.01, ***p < 0.001).
    Human Prostate Cancer Cell Lines Pc3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/pm41858228-38-0-12?v=ATCC
    Average 99 stars, based on 1 article reviews
    human prostate cancer cell lines pc3 - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC human metastatic prostate cancer cell line pc 3
    Engineering hPSMA-CARs with mbIL12 rescues CAR T cell functionality a Schema of hPSMA-CAR variants with mbIL12 expression. b Flow cytometric analysis of ET260-1 CAR and ET260-1(58) CAR with or without mbIL12 as detected by extracellular Fc and intracellular IL-12. c Tumor cell killing of hPSMA-CARs at an E:T of 1:4 over 72 hrs. d Expression of 4-1BB over 72 hrs on hPSMA-CARs. e Expression of CD25 on hPSMA-CARs after 72 hrs. f Secretion of IFNγ of hPSMA-CARs with mbIL12 after 72 hrs as determined by ELISA. g Tumor cell killing of hPSMA-CARs with mbIL12 and J591 <t>against</t> <t>PC-3</t> PIP at E:T of 1:10 over 5 days at varying concentrations of anti-IFNγR1 blocking antibody and isotype control. Data are presented as mean values ± SEM. P values indicate differences between ET260-1-dCH2(28tm)BBz and ET260-1-dCH2(28tm)BBz/mbIL12 and between ET260-1-dCH2(28tm)BBz/mbIL12 and J591-dCH2(4tm)BBz using a two-tailed Student’s t-test.
    Human Metastatic Prostate Cancer Cell Line Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+cancer+cell+lines+pc/bio_rxiv__64898__2026__03__05__709907-145-0-7?v=ATCC
    Average 99 stars, based on 1 article reviews
    human metastatic prostate cancer cell line pc 3 - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    Image Search Results


    ( a ) A schematic workflow illustrating the preclinical therapeutic procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 recombinants, severe combined immunodeficient (M-NSG) mice were subject to either single agent or combinatorial treatment in a metronomic schedule of several cycles. The illustration was created in BioRender. ( b ) Comparative statistics of tumor end volumes. PC3 cancer cells were inoculated either alone or combined with PSC27 stromal cells before being implanted subcutaneously to the hind flank of M-NSG animals, which were administered with MIT and SAA, either alone or in combination. ( c ) Representative images of in vivo senescence in tumor foci by SA-β-gal staining. Scale bar, 50 μm. ( d ) Comparative statistics of tumor senescence as described in ( c ). ( e ) Transcriptional analysis of a subset of SASP factors expressed in epithelial vs. stromal cells acquired from tumor foci after laser capture microdissection (LCM) to isolate stromal and cancer cells, respectively. Signals were normalized to that of the sample with lowest value in the placebo group. ( f ) Transcriptional analysis of SASP factors and two canonical senescence biomarkers p16 INK4a and p21 CIP1 . ( g ) Statistical assessment of DDR and cellular apoptosis in tumors. Values are shown as the percentage of cells positively stained by IF or IHC specific to γH2AX or cleaved caspase 3 (CCL3), respectively. ( h ) Representative images of IHC staining for CCL3 at the completion of treatment regimens. Scale bar, 50 μm. ( i ) Comparative survival of animals sacrificed upon development of advanced bulky disease. Survival duration was calculated from tissue recombinant injection until death. P values were calculated by a two-sided log-rank (Mantel-Cox) test. DDR, DNA damage response. IF, immunofluorescence. IHC, immunohistochemistry. Data in b , d , e , f and g are shown as mean ± SD and representative of 3 independent biological replicates, with P values calculated by Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Journal: bioRxiv

    Article Title: Salvianolic acids are natural senolytics and increase lifespan in old age

    doi: 10.64898/2026.04.29.721790

    Figure Lengend Snippet: ( a ) A schematic workflow illustrating the preclinical therapeutic procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 recombinants, severe combined immunodeficient (M-NSG) mice were subject to either single agent or combinatorial treatment in a metronomic schedule of several cycles. The illustration was created in BioRender. ( b ) Comparative statistics of tumor end volumes. PC3 cancer cells were inoculated either alone or combined with PSC27 stromal cells before being implanted subcutaneously to the hind flank of M-NSG animals, which were administered with MIT and SAA, either alone or in combination. ( c ) Representative images of in vivo senescence in tumor foci by SA-β-gal staining. Scale bar, 50 μm. ( d ) Comparative statistics of tumor senescence as described in ( c ). ( e ) Transcriptional analysis of a subset of SASP factors expressed in epithelial vs. stromal cells acquired from tumor foci after laser capture microdissection (LCM) to isolate stromal and cancer cells, respectively. Signals were normalized to that of the sample with lowest value in the placebo group. ( f ) Transcriptional analysis of SASP factors and two canonical senescence biomarkers p16 INK4a and p21 CIP1 . ( g ) Statistical assessment of DDR and cellular apoptosis in tumors. Values are shown as the percentage of cells positively stained by IF or IHC specific to γH2AX or cleaved caspase 3 (CCL3), respectively. ( h ) Representative images of IHC staining for CCL3 at the completion of treatment regimens. Scale bar, 50 μm. ( i ) Comparative survival of animals sacrificed upon development of advanced bulky disease. Survival duration was calculated from tissue recombinant injection until death. P values were calculated by a two-sided log-rank (Mantel-Cox) test. DDR, DNA damage response. IF, immunofluorescence. IHC, immunohistochemistry. Data in b , d , e , f and g are shown as mean ± SD and representative of 3 independent biological replicates, with P values calculated by Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Article Snippet: The human prostate epithelial cancer cell line, PC3, was from ATCC and cultured with F-12K media (10% FBS).

    Techniques: In Vivo, Staining, Laser Capture Microdissection, Immunohistochemistry, Recombinant, Injection, Immunofluorescence

    PhIP exposure induces cytotoxicity in RWPE-1 cells and downregulates SLC14A1 expression in PC-3 cells. (A) Immunohistochemical staining of SLC14A1 in prostate cancer tissues and normal prostate tissues based on data from the HPA database. (B) Cell viability of RWPE-1 cells after treatment with increasing concentrations of PhIP for 48 h, as determined by CCK-8 assay. (C) Protein expression levels of SLC14A1 in PC-3 cells following PhIP treatment, as assessed by Western blot. (D) Relative mRNA expression levels of SLC14A1 in PC-3 cells after PhIP treatment, as determined by qRT-PCR (**p < 0.01, ***p < 0.001).

    Journal: Frontiers in Immunology

    Article Title: PhIP-driven prostate cancer involves key molecular regulators and immune microenvironment modulation

    doi: 10.3389/fimmu.2026.1782240

    Figure Lengend Snippet: PhIP exposure induces cytotoxicity in RWPE-1 cells and downregulates SLC14A1 expression in PC-3 cells. (A) Immunohistochemical staining of SLC14A1 in prostate cancer tissues and normal prostate tissues based on data from the HPA database. (B) Cell viability of RWPE-1 cells after treatment with increasing concentrations of PhIP for 48 h, as determined by CCK-8 assay. (C) Protein expression levels of SLC14A1 in PC-3 cells following PhIP treatment, as assessed by Western blot. (D) Relative mRNA expression levels of SLC14A1 in PC-3 cells after PhIP treatment, as determined by qRT-PCR (**p < 0.01, ***p < 0.001).

    Article Snippet: The human prostatic epithelial cell line RWPE-1 and the human prostate cancer cell line PC-3 were obtained from the American Type Culture Collection (ATCC).

    Techniques: Expressing, Immunohistochemical staining, Staining, CCK-8 Assay, Western Blot, Quantitative RT-PCR

    Engineering hPSMA-CARs with mbIL12 rescues CAR T cell functionality a Schema of hPSMA-CAR variants with mbIL12 expression. b Flow cytometric analysis of ET260-1 CAR and ET260-1(58) CAR with or without mbIL12 as detected by extracellular Fc and intracellular IL-12. c Tumor cell killing of hPSMA-CARs at an E:T of 1:4 over 72 hrs. d Expression of 4-1BB over 72 hrs on hPSMA-CARs. e Expression of CD25 on hPSMA-CARs after 72 hrs. f Secretion of IFNγ of hPSMA-CARs with mbIL12 after 72 hrs as determined by ELISA. g Tumor cell killing of hPSMA-CARs with mbIL12 and J591 against PC-3 PIP at E:T of 1:10 over 5 days at varying concentrations of anti-IFNγR1 blocking antibody and isotype control. Data are presented as mean values ± SEM. P values indicate differences between ET260-1-dCH2(28tm)BBz and ET260-1-dCH2(28tm)BBz/mbIL12 and between ET260-1-dCH2(28tm)BBz/mbIL12 and J591-dCH2(4tm)BBz using a two-tailed Student’s t-test.

    Journal: bioRxiv

    Article Title: IL12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer

    doi: 10.64898/2026.03.05.709907

    Figure Lengend Snippet: Engineering hPSMA-CARs with mbIL12 rescues CAR T cell functionality a Schema of hPSMA-CAR variants with mbIL12 expression. b Flow cytometric analysis of ET260-1 CAR and ET260-1(58) CAR with or without mbIL12 as detected by extracellular Fc and intracellular IL-12. c Tumor cell killing of hPSMA-CARs at an E:T of 1:4 over 72 hrs. d Expression of 4-1BB over 72 hrs on hPSMA-CARs. e Expression of CD25 on hPSMA-CARs after 72 hrs. f Secretion of IFNγ of hPSMA-CARs with mbIL12 after 72 hrs as determined by ELISA. g Tumor cell killing of hPSMA-CARs with mbIL12 and J591 against PC-3 PIP at E:T of 1:10 over 5 days at varying concentrations of anti-IFNγR1 blocking antibody and isotype control. Data are presented as mean values ± SEM. P values indicate differences between ET260-1-dCH2(28tm)BBz and ET260-1-dCH2(28tm)BBz/mbIL12 and between ET260-1-dCH2(28tm)BBz/mbIL12 and J591-dCH2(4tm)BBz using a two-tailed Student’s t-test.

    Article Snippet: Human metastatic prostate cancer cell line PC-3 (ATCC CRL-1435) was cultured in RPMI-1640 (Corning) containing 10% fetal bovine serum (FBS, Hyclone), and 1X antibiotic-antimycotic (AA, Gibco) (complete RPMI).

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Blocking Assay, Control, Two Tailed Test

    mbIL12-engineered hPSMA-CAR T cells demonstrate improved activity in a recursive tumor cell assay in vitro a Tumor cell killing of hPSMA-CARs over 8 days when co-cultured with PSMA-expressing cell lines at E:T of 1:20. b Fold expansion of hPSMA-CARs compared to J591-CAR after 8-day co-culture. c Production of IFNγ at 8 days as determined by ELISA. d Schema of rechallenge with PSMA-CARs co-cultured with PC-3 PSMA lo , PC-3 PSMA hi , or PC-3 PIP and rechallenged with tumor cells every 3 days. e PC-3 PSMA lo (left), PC-3 PSMA hi (center), or PC-3 PIP (right) cell counts were quantified by flow cytometry. b Fold expansion of T cells after each rechallenge were quantified by flow cytometry. c Production of IFNγ by T cells following each rechallenge as determined by ELISA. Data are presented as mean values ± SEM. P values indicate differences between ET260-1-dCH2(28tm)BBz and ET260-1-dCH2(28tm)BBz/mbIL12 and between ET260-1-dCH2(28tm)BBz/mbIL12 and J591-dCH2(4tm)BBz using a two-tailed Student’s t-test.

    Journal: bioRxiv

    Article Title: IL12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer

    doi: 10.64898/2026.03.05.709907

    Figure Lengend Snippet: mbIL12-engineered hPSMA-CAR T cells demonstrate improved activity in a recursive tumor cell assay in vitro a Tumor cell killing of hPSMA-CARs over 8 days when co-cultured with PSMA-expressing cell lines at E:T of 1:20. b Fold expansion of hPSMA-CARs compared to J591-CAR after 8-day co-culture. c Production of IFNγ at 8 days as determined by ELISA. d Schema of rechallenge with PSMA-CARs co-cultured with PC-3 PSMA lo , PC-3 PSMA hi , or PC-3 PIP and rechallenged with tumor cells every 3 days. e PC-3 PSMA lo (left), PC-3 PSMA hi (center), or PC-3 PIP (right) cell counts were quantified by flow cytometry. b Fold expansion of T cells after each rechallenge were quantified by flow cytometry. c Production of IFNγ by T cells following each rechallenge as determined by ELISA. Data are presented as mean values ± SEM. P values indicate differences between ET260-1-dCH2(28tm)BBz and ET260-1-dCH2(28tm)BBz/mbIL12 and between ET260-1-dCH2(28tm)BBz/mbIL12 and J591-dCH2(4tm)BBz using a two-tailed Student’s t-test.

    Article Snippet: Human metastatic prostate cancer cell line PC-3 (ATCC CRL-1435) was cultured in RPMI-1640 (Corning) containing 10% fetal bovine serum (FBS, Hyclone), and 1X antibiotic-antimycotic (AA, Gibco) (complete RPMI).

    Techniques: Activity Assay, In Vitro, Cell Culture, Expressing, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Two Tailed Test